Adona Medical

Executive Summary

Adona Medical is a private medical device company developing a novel, minimally invasive interatrial shunt system for the management of heart failure. The company's investigational platform integrates an adjustable shunt with bi-atrial pressure sensors, enabling personalized, titratable therapy based on direct hemodynamic measurements. Founded in 2015 and operating as a portfolio company of Shifamed, a renowned medical device incubator, Adona addresses the significant unmet need in heart failure treatment by offering a dynamic, adjustable solution that can be optimized over time. The adjustable nature of the shunt, combined with real-time pressure sensing, holds the potential to improve outcomes compared to fixed-size shunts currently in development. With a focused approach on hemodynamic-guided therapy, Adona is positioned to capture value in the growing heart failure device market, estimated to reach billions in the coming decade. Adona's technology is still in the investigational stage, with no publicly disclosed clinical data to date. However, the platform's unique aspect of adjustability and sensor integration may offer a competitive advantage over other interatrial shunt devices. The company's success hinges on demonstrating safety and efficacy in clinical trials, securing regulatory approvals, and establishing reimbursement. Key upcoming milestones include the initiation of first-in-human studies and potential partnerships or funding rounds to support clinical development. As a private company, Adona's progress is closely watched by investors in the cardiovascular device space, and its innovative approach could reshape the management of heart failure if proven successful.

Upcoming Catalysts (preview)

• Q3 2026Initiation of first-in-human clinical study70% success
• Q4 2026Series B or later financing round60% success
• Q2 2026FDA Breakthrough Device designation80% success